Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 36 entries
Sorted by: Best Match Show Resources per page
Detection of radon emission at the edges of lunar maria with the apollo alpha-particle spectrometer.

Science (New York, N.Y.)

Gorenstein P, Golub L, Bjorkholm P.
PMID: 17781931
Science. 1974 Feb 01;183(4123):411-3. doi: 10.1126/science.183.4123.411.

The distribution of radioactive polonium-210, a decay product of radon-222, shows enhanced concentrations at the edges of lunar maria. Enhancements are seen at the edges of Mare Fecunditatis, Mare Crisium, Mare Smythii. Mare Tranquillitatis, Mare Nubium, Mare Cognitum, and...

Cite
Gorenstein P, Golub L, Bjorkholm P. Detection of radon emission at the edges of lunar maria with the apollo alpha-particle spectrometer. Science. 1974;183(4123):411-3doi: 10.1126/science.183.4123.411.
Gorenstein, P., Golub, L., & Bjorkholm, P. (1974). Detection of radon emission at the edges of lunar maria with the apollo alpha-particle spectrometer. Science (New York, N.Y.), 183(4123), 411-3. https://doi.org/10.1126/science.183.4123.411
Gorenstein, P, et al. "Detection of radon emission at the edges of lunar maria with the apollo alpha-particle spectrometer." Science (New York, N.Y.) vol. 183,4123 (1974): 411-3. doi: https://doi.org/10.1126/science.183.4123.411
Gorenstein P, Golub L, Bjorkholm P. Detection of radon emission at the edges of lunar maria with the apollo alpha-particle spectrometer. Science. 1974 Feb 01;183(4123):411-3. doi: 10.1126/science.183.4123.411. PMID: 17781931.
Copy Download .nbib Format: NLM
Detection of radon emanation from the crater aristarchus by the apollo 15 alpha particle spectrometer.

Science (New York, N.Y.)

Gorenstein P, Bjorkholm P.
PMID: 17806295
Science. 1973 Feb 23;179(4075):792-4. doi: 10.1126/science.179.4075.792.

The alpha particle spectrometer aboard the Apollo 15 command/service module was designed to detect alpha particles from radon decay and to locate regions with unusual activity on the moon. A significant increase in radon-222 activity was detected from a...

Cite
Gorenstein P, Bjorkholm P. Detection of radon emanation from the crater aristarchus by the apollo 15 alpha particle spectrometer. Science. 1973;179(4075):792-4doi: 10.1126/science.179.4075.792.
Gorenstein, P., & Bjorkholm, P. (1973). Detection of radon emanation from the crater aristarchus by the apollo 15 alpha particle spectrometer. Science (New York, N.Y.), 179(4075), 792-4. https://doi.org/10.1126/science.179.4075.792
Gorenstein, P, and Bjorkholm, P. "Detection of radon emanation from the crater aristarchus by the apollo 15 alpha particle spectrometer." Science (New York, N.Y.) vol. 179,4075 (1973): 792-4. doi: https://doi.org/10.1126/science.179.4075.792
Gorenstein P, Bjorkholm P. Detection of radon emanation from the crater aristarchus by the apollo 15 alpha particle spectrometer. Science. 1973 Feb 23;179(4075):792-4. doi: 10.1126/science.179.4075.792. PMID: 17806295.
Copy Download .nbib Format: NLM
Lymphoblastoid cell line with B1 cell characteristics established from a chronic lymphocytic leukemia clone by in vitro EBV infection.

Oncoimmunology

Rosén A, Bergh AC, Gogok P, Evaldsson C, Myhrinder AL, Hellqvist E, Rasul A, Björkholm M, Jansson M, Mansouri L, Liu A, Teh BT, Rosenquist R, Klein E.
PMID: 22720208
Oncoimmunology. 2012 Jan 01;1(1):18-27. doi: 10.4161/onci.1.1.18400.

Chronic lymphocytic leukemia (CLL) cells express the receptor for Epstein-Barr virus (EBV) and can be infected in vitro. Infected cells do not express the growth-promoting set of EBV-encoded genes and therefore they do not yield LCLs, in most experiments....

Cite
Rosén A, Bergh AC, Gogok P, et al. Lymphoblastoid cell line with B1 cell characteristics established from a chronic lymphocytic leukemia clone by in vitro EBV infection. Oncoimmunology. 2012;1(1):18-27doi: 10.4161/onci.1.1.18400.
Rosén, A., Bergh, A. C., Gogok, P., Evaldsson, C., Myhrinder, A. L., Hellqvist, E., Rasul, A., Björkholm, M., Jansson, M., Mansouri, L., Liu, A., Teh, B. T., Rosenquist, R., & Klein, E. (2012). Lymphoblastoid cell line with B1 cell characteristics established from a chronic lymphocytic leukemia clone by in vitro EBV infection. Oncoimmunology, 1(1), 18-27. https://doi.org/10.4161/onci.1.1.18400
Rosén, Anders, et al. "Lymphoblastoid cell line with B1 cell characteristics established from a chronic lymphocytic leukemia clone by in vitro EBV infection." Oncoimmunology vol. 1,1 (2012): 18-27. doi: https://doi.org/10.4161/onci.1.1.18400
Rosén A, Bergh AC, Gogok P, Evaldsson C, Myhrinder AL, Hellqvist E, Rasul A, Björkholm M, Jansson M, Mansouri L, Liu A, Teh BT, Rosenquist R, Klein E. Lymphoblastoid cell line with B1 cell characteristics established from a chronic lymphocytic leukemia clone by in vitro EBV infection. Oncoimmunology. 2012 Jan 01;1(1):18-27. doi: 10.4161/onci.1.1.18400. PMID: 22720208; PMCID: PMC3376971.
Copy Download .nbib Format: NLM
Correction to: MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia.

Annals of hematology

Zhang X, Li B, Yu J, Dahlström J, Tran AN, Björkholm M, Xu D.
PMID: 29744585
Ann Hematol. 2018 Jul;97(7):1299. doi: 10.1007/s00277-018-3340-7.

The original version of this article contained a mistake. The name of Magnus Björkhom should have been Magnus Björkholm.

Cite
Zhang X, Li B, Yu J, et al. Correction to: MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia. Ann Hematol. 2018;97(7):1299doi: 10.1007/s00277-018-3340-7.
Zhang, X., Li, B., Yu, J., Dahlström, J., Tran, A. N., Björkholm, M., & Xu, D. (2018). Correction to: MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia. Annals of hematology, 97(7), 1299. https://doi.org/10.1007/s00277-018-3340-7
Zhang, Xiaolu, et al. "Correction to: MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia." Annals of hematology vol. 97,7 (2018): 1299. doi: https://doi.org/10.1007/s00277-018-3340-7
Zhang X, Li B, Yu J, Dahlström J, Tran AN, Björkholm M, Xu D. Correction to: MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia. Ann Hematol. 2018 Jul;97(7):1299. doi: 10.1007/s00277-018-3340-7. PMID: 29744585; PMCID: PMC6828086.
Copy Download .nbib Format: NLM
Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival.

European journal of haematology

Turesson I, Bjorkholm M, Blimark CH, Kristinsson S, Velez R, Landgren O.
PMID: 29676004
Eur J Haematol. 2018 Apr 20; doi: 10.1111/ejh.13083. Epub 2018 Apr 20.

The incidence of multiple myeloma is characterized by a steep increase with advancing age. Dramatic improvements in survival have been reported in clinical trials; however, elderly patients are generally underrepresented in these. The aims of this study are to...

Cite
Turesson I, Bjorkholm M, Blimark CH, et al. Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival. Eur J Haematol. 2018;doi: 10.1111/ejh.13083.
Turesson, I., Bjorkholm, M., Blimark, C. H., Kristinsson, S., Velez, R., & Landgren, O. (2018). Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival. European journal of haematology, . https://doi.org/10.1111/ejh.13083
Turesson, Ingemar, et al. "Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival." European journal of haematology vol. (2018). doi: https://doi.org/10.1111/ejh.13083
Turesson I, Bjorkholm M, Blimark CH, Kristinsson S, Velez R, Landgren O. Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival. Eur J Haematol. 2018 Apr 20; doi: 10.1111/ejh.13083. Epub 2018 Apr 20. PMID: 29676004; PMCID: PMC6195866.
Copy Download .nbib Format: NLM
Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.

JAMA oncology

Landgren O, Hofmann JN, McShane CM, Santo L, Hultcrantz M, Korde N, Mailankody S, Kazandjian D, Murata K, Thoren K, Ramanathan L, Dogan A, Rustad E, Lu SX, Akhlaghi T, Kristinsson SY, Björkholm M, Devlin S, Purdue MP, Pfeiffer RM, Turesson I.
PMID: 31318385
JAMA Oncol. 2019 Sep 01;5(9):1293-1301. doi: 10.1001/jamaoncol.2019.1568.

IMPORTANCE: Multiple myeloma is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS). Risk models that estimate the risk of progression from MGUS to multiple myeloma use data from a single time point, usually the initial workup.OBJECTIVE: To longitudinally...

Cite
Landgren O, Hofmann JN, McShane CM, et al. Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. JAMA Oncol. 2019;5(9):1293-1301doi: 10.1001/jamaoncol.2019.1568.
Landgren, O., Hofmann, J. N., McShane, C. M., Santo, L., Hultcrantz, M., Korde, N., Mailankody, S., Kazandjian, D., Murata, K., Thoren, K., Ramanathan, L., Dogan, A., Rustad, E., Lu, S. X., Akhlaghi, T., Kristinsson, S. Y., Björkholm, M., Devlin, S., Purdue, M. P., Pfeiffer, R. M., & Turesson, I. (2019). Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. JAMA oncology, 5(9), 1293-1301. https://doi.org/10.1001/jamaoncol.2019.1568
Landgren, Ola, et al. "Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma." JAMA oncology vol. 5,9 (2019): 1293-1301. doi: https://doi.org/10.1001/jamaoncol.2019.1568
Landgren O, Hofmann JN, McShane CM, Santo L, Hultcrantz M, Korde N, Mailankody S, Kazandjian D, Murata K, Thoren K, Ramanathan L, Dogan A, Rustad E, Lu SX, Akhlaghi T, Kristinsson SY, Björkholm M, Devlin S, Purdue MP, Pfeiffer RM, Turesson I. Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. JAMA Oncol. 2019 Sep 01;5(9):1293-1301. doi: 10.1001/jamaoncol.2019.1568. PMID: 31318385; PMCID: PMC6646992.
Copy Download .nbib Format: NLM
Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls.

Haematologica

Shah UA, Rögnvaldsson S, Derkach A, Björkholm M, Turesson I, David Y, Hultcrantz M, Tan C, Hassoun H, Korde N, Lesokhin A, Mailankody S, Kristinsson SY, Landgren CO.
PMID: 34474548
Haematologica. 2022 Jan 01;107(1):284-286. doi: 10.3324/haematol.2021.278772.

No abstract available.

Cite
Shah UA, Rögnvaldsson S, Derkach A, et al. Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls. Haematologica. 2022;107(1):284-286doi: 10.3324/haematol.2021.278772.
Shah, U. A., Rögnvaldsson, S., Derkach, A., Björkholm, M., Turesson, I., David, Y., Hultcrantz, M., Tan, C., Hassoun, H., Korde, N., Lesokhin, A., Mailankody, S., Kristinsson, S. Y., & Landgren, C. O. (2022). Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls. Haematologica, 107(1), 284-286. https://doi.org/10.3324/haematol.2021.278772
Shah, Urvi A, et al. "Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls." Haematologica vol. 107,1 (2022): 284-286. doi: https://doi.org/10.3324/haematol.2021.278772
Shah UA, Rögnvaldsson S, Derkach A, Björkholm M, Turesson I, David Y, Hultcrantz M, Tan C, Hassoun H, Korde N, Lesokhin A, Mailankody S, Kristinsson SY, Landgren CO. Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls. Haematologica. 2022 Jan 01;107(1):284-286. doi: 10.3324/haematol.2021.278772. PMID: 34474548; PMCID: PMC8719074.
Copy Download .nbib Format: NLM
Untangling fracture risk in monoclonal gammopathy of undetermined significance: A population-based cohort study.

European journal of haematology

Rögnvaldsson S, Aspelund T, Thorsteinsdóttir S, Turesson I, Björkholm M, Landgren O, Kristinsson SY.
PMID: 33840154
Eur J Haematol. 2021 Jul;107(1):137-144. doi: 10.1111/ejh.13633. Epub 2021 Apr 28.

OBJECTIVE: Monoclonal gammopathy of undetermined significance (MGUS) is the asymptomatic precursor of multiple myeloma (MM). Lytic bone lesions and fractures are hallmarks of MM and although there are no lytic lesions in MGUS, it has also been associated with...

Cite
Rögnvaldsson S, Aspelund T, Thorsteinsdóttir S, et al. Untangling fracture risk in monoclonal gammopathy of undetermined significance: A population-based cohort study. Eur J Haematol. 2021;107(1):137-144doi: 10.1111/ejh.13633.
Rögnvaldsson, S., Aspelund, T., Thorsteinsdóttir, S., Turesson, I., Björkholm, M., Landgren, O., & Kristinsson, S. Y. (2021). Untangling fracture risk in monoclonal gammopathy of undetermined significance: A population-based cohort study. European journal of haematology, 107(1), 137-144. https://doi.org/10.1111/ejh.13633
Rögnvaldsson, Saemundur, et al. "Untangling fracture risk in monoclonal gammopathy of undetermined significance: A population-based cohort study." European journal of haematology vol. 107,1 (2021): 137-144. doi: https://doi.org/10.1111/ejh.13633
Rögnvaldsson S, Aspelund T, Thorsteinsdóttir S, Turesson I, Björkholm M, Landgren O, Kristinsson SY. Untangling fracture risk in monoclonal gammopathy of undetermined significance: A population-based cohort study. Eur J Haematol. 2021 Jul;107(1):137-144. doi: 10.1111/ejh.13633. Epub 2021 Apr 28. PMID: 33840154.
Copy Download .nbib Format: NLM
Regulatory region mutations of .

Journal of Cancer

Xing X, Yuan X, Liu T, Dai M, Fan Y, Liu C, Strååt K, Björkholm M, Xu D.
PMID: 34093793
J Cancer. 2021 May 05;12(13):3853-3861. doi: 10.7150/jca.56779. eCollection 2021.

No abstract available.

Cite
Xing X, Yuan X, Liu T, et al. Regulatory region mutations of . J Cancer. 2021;12(13):3853-3861doi: 10.7150/jca.56779.
Xing, X., Yuan, X., Liu, T., Dai, M., Fan, Y., Liu, C., Strååt, K., Björkholm, M., & Xu, D. (2021). Regulatory region mutations of . Journal of Cancer, 12(13), 3853-3861. https://doi.org/10.7150/jca.56779
Xing, Xiangling, et al. "Regulatory region mutations of ." Journal of Cancer vol. 12,13 (2021): 3853-3861. doi: https://doi.org/10.7150/jca.56779
Xing X, Yuan X, Liu T, Dai M, Fan Y, Liu C, Strååt K, Björkholm M, Xu D. Regulatory region mutations of . J Cancer. 2021 May 05;12(13):3853-3861. doi: 10.7150/jca.56779. eCollection 2021. PMID: 34093793; PMCID: PMC8176235.
Copy Download .nbib Format: NLM
Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma.

Blood

Meriranta L, Alkodsi A, Pasanen A, Lepistö M, Mapar P, Blaker YN, Jørgensen JM, Karjalainen-Lindsberg ML, Fiskvik I, Mikalsen LTG, Autio M, Björkholm M, Jerkeman M, Fluge Ø, Brown P, Jyrkkiö S, Holte H, Pitkänen E, Ellonen P, Leppa S.
PMID: 34932792
Blood. 2021 Dec 21; doi: 10.1182/blood.2021012852. Epub 2021 Dec 21.

Inadequate molecular and clinical stratification of the patients with high-risk diffuse large B-cell lymphoma (DLBCL) is a clinical challenge hampering the establishment of personalized therapeutic options. We studied the translational significance of liquid biopsy in a uniformly treated trial...

Cite
Meriranta L, Alkodsi A, Pasanen A, et al. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. Blood. 2021;doi: 10.1182/blood.2021012852.
Meriranta, L., Alkodsi, A., Pasanen, A., Lepistö, M., Mapar, P., Blaker, Y. N., Jørgensen, J. M., Karjalainen-Lindsberg, M. L., Fiskvik, I., Mikalsen, L. T. G., Autio, M., Björkholm, M., Jerkeman, M., Fluge, �. �., Brown, P., Jyrkkiö, S., Holte, H., Pitkänen, E., Ellonen, P., & Leppa, S. (2021). Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. Blood, . https://doi.org/10.1182/blood.2021012852
Meriranta, Leo, et al. "Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma." Blood vol. (2021). doi: https://doi.org/10.1182/blood.2021012852
Meriranta L, Alkodsi A, Pasanen A, Lepistö M, Mapar P, Blaker YN, Jørgensen JM, Karjalainen-Lindsberg ML, Fiskvik I, Mikalsen LTG, Autio M, Björkholm M, Jerkeman M, Fluge Ø, Brown P, Jyrkkiö S, Holte H, Pitkänen E, Ellonen P, Leppa S. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. Blood. 2021 Dec 21; doi: 10.1182/blood.2021012852. Epub 2021 Dec 21. PMID: 34932792.
Copy Download .nbib Format: NLM
Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma.

Blood

Meriranta L, Alkodsi A, Pasanen A, Lepistö M, Mapar P, Blaker YN, Jørgensen JM, Karjalainen-Lindsberg ML, Fiskvik I, Mikalsen LTG, Autio M, Björkholm M, Jerkeman M, Fluge Ø, Brown P, Jyrkkiö S, Holte H, Pitkänen E, Ellonen P, Leppa S.
PMID: 34932792
Blood. 2021 Dec 21; doi: 10.1182/blood.2021012852. Epub 2021 Dec 21.

Inadequate molecular and clinical stratification of the patients with high-risk diffuse large B-cell lymphoma (DLBCL) is a clinical challenge hampering the establishment of personalized therapeutic options. We studied the translational significance of liquid biopsy in a uniformly treated trial...

Cite
Meriranta L, Alkodsi A, Pasanen A, et al. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. Blood. 2021;doi: 10.1182/blood.2021012852.
Meriranta, L., Alkodsi, A., Pasanen, A., Lepistö, M., Mapar, P., Blaker, Y. N., Jørgensen, J. M., Karjalainen-Lindsberg, M. L., Fiskvik, I., Mikalsen, L. T. G., Autio, M., Björkholm, M., Jerkeman, M., Fluge, �. �., Brown, P., Jyrkkiö, S., Holte, H., Pitkänen, E., Ellonen, P., & Leppa, S. (2021). Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. Blood, . https://doi.org/10.1182/blood.2021012852
Meriranta, Leo, et al. "Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma." Blood vol. (2021). doi: https://doi.org/10.1182/blood.2021012852
Meriranta L, Alkodsi A, Pasanen A, Lepistö M, Mapar P, Blaker YN, Jørgensen JM, Karjalainen-Lindsberg ML, Fiskvik I, Mikalsen LTG, Autio M, Björkholm M, Jerkeman M, Fluge Ø, Brown P, Jyrkkiö S, Holte H, Pitkänen E, Ellonen P, Leppa S. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. Blood. 2021 Dec 21; doi: 10.1182/blood.2021012852. Epub 2021 Dec 21. PMID: 34932792.
Copy Download .nbib Format: NLM
Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms.

Genome medicine

Goldin LR, Björkholm M, Kristinsson SY, Samuelsson J, Landgren O.
PMID: 19490586
Genome Med. 2009 May 29;1(5):55. doi: 10.1186/gm55.

Myeloproliferative neoplasms (MPNs) are a group of closely related stem-cell-derived clonal proliferative diseases. Most cases are sporadic but first-degree relatives of MPN patients have a five- to seven-fold increased risk for developing an MPN. The tumors of most patients...

Cite
Goldin LR, Björkholm M, Kristinsson SY, et al. Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms. Genome Med. 2009;1(5):55doi: 10.1186/gm55.
Goldin, L. R., Björkholm, M., Kristinsson, S. Y., Samuelsson, J., & Landgren, O. (2009). Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms. Genome medicine, 1(5), 55. https://doi.org/10.1186/gm55
Goldin, Lynn R, et al. "Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms." Genome medicine vol. 1,5 (2009): 55. doi: https://doi.org/10.1186/gm55
Goldin LR, Björkholm M, Kristinsson SY, Samuelsson J, Landgren O. Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms. Genome Med. 2009 May 29;1(5):55. doi: 10.1186/gm55. PMID: 19490586; PMCID: PMC2689447.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 36 entries